

# LeptoX

***Game-Changing Vaccine Development for  
Life-Threatening Bacterial Infections***



GlimmerX

# The LeptoX Team



**Joe Vinetz, M.D.**  
**Scientific Consultant**  
Professor, Yale School of Medicine  
*International scientific reputation; experienced in managing and executing complex projects*



**Carla Devillers, M.B.A.**  
**Founding Executive**  
*Wharton M.B.A.*  
*Highly experienced international finance, operations, and business development executive*



**Tsvi Goldenberg, Ph.D**  
**Partner**  
*Experienced innovator in start-ups*  
*Serial entrepreneur*




Wilson Sonsini Goodrich & Rosati:  
Global intellectual property and corporate lawyers



**Yale Accelerator for Innovation Development Team:**  
Colleen Lopez, PhD  
Eva Leung  
Konstantine Drakonakis

# The Problem

Leptospirosis is the Ebola virus of the bacterial world



The vaccine for human leptospirosis is **unsafe and of unknown efficacy**, yet a vast domestic and global need remains



Threat to Travelers



Threat to Soldiers



Global Health Threat



# The Solution: LeptoX




LeptoX holds patented technology to develop **safer and more effective** vaccines for human and animal leptospirosis and other unmet needs


# The LeptoX Technology

- Novel IP/discovery focused on unmet needs
- Able to translate discovery to global scale clinical testing sites
- Recognized field-leading founding scientist with track record of organizing and obtaining funding for complex projects
  - ✓ Demonstrated ability to attract funding
  - ✓ Raised more than \$48 million in NIH grants since 2000
  - ✓ Potential for non-dilutive federal funds (SBIR, military, BARDA)


Previous work



*L. Interrogans*  
Serovar Copenhageni




Our novel IP




# Scope of the Opportunity

Scalable glycoconjugate platform with huge potential to capture both **HUMAN** and **ANIMAL** segments for leptospirosis  
Leptospirosis vaccine development for **animals** enables expedited approval for human leptospirosis vaccine



## POTENTIAL DOMESTIC MARKET VALUE 2020 (IN THOUSANDS)



# Our Offering vs. Competition (Veterinary)



Provider	Vaccine Type	Efficacy	Duration	Safety
LeptoX	Glycoconjugate, Purified LPS	+++++	+++++	+++++
Zoetis	Bacterin	+	+	+
Merck	Bacterin	+	+	+
Boeringer- Ingelheim	Bacterin	+	+	+

# Blavatnik Funds will enable:



## YEAR 1

- Protection of current and new IP
- Creating team of dedicated scientists
- Wet lab space
- Matching funds from CT Innovations
- Prototypes/candidates in hand at 1 year
  - Vaccine: Initial formulations for animal model testing

## YEAR 2 – 3

- New, nondilutive funding; early stage investment
- Create SOPs/protocols to enable pilot cGMP vaccine production
- Vaccine production scale up
  - For clinical testing in endemic sites
  - Licensing partners for manufacture/distribution
- Veterinary trial testing

## YEAR 4 – 5

- Early stage investment
- cGMP production of vaccine
- Preclinical testing begins
- Prepare for IND/Phase I human clinical trials



# Thank You!



## Questions?

### Contact

**Joseph Vinetz, M.D.**  
joseph.vinetz@yale.edu

**Carla Devillers, M.B.A.**  
carladevillers@gmail.com